- Company
- Ibrance and Verzenio settle pricing for Faslodex combination
- by Eo, Yun-Ho May 14, 2020 06:24am
- At last, Faslodex plus CDK4/6 inhibitor combination therapy would be accessible as an actual treatment option for patients. According to Korean pharmaceutical industry sources, two cyclin-dependent kinases 4/6 (CDK4/6) inhibitors including Pfizer’s Ibrance (palbociclib) and Lilly's Verzenio (abemaciclib) treating patients with HER2-neg
- Company
- Korean companies to showcase clinical data at ASCO 2020
- by An, Kyung-Jin May 14, 2020 06:24am
- The American Society of Clinical Oncology Annual Meeting (ASCO) 2020 is coming up in a couple of weeks. The 56th ASCO is one of the biggest pharmaceutical and bio industry events along with JP Morgan Healthcare Conference. Every year, about 40,000 pharmaceutical and bio industry and academic representatives are invited to the conference in
- Company
- α-GPC has been prescribed more than twice in 3 years
- by Chon, Seung-Hyun May 14, 2020 06:23am
- Sales of Choline alfoscerate, a brain function improving agent, continue to grow. The effectiveness controversy has recently been raised, but the market size has increased by more than 20% this year. Over the past three years, the market size has doubled, exceeding the quarterly prescription size of &8361;100 billion. However, the decline was s
- Company
- New osteoporosis drug Evenity applies for reimbursement
- by Eo, Yun-Ho May 13, 2020 05:54am
- Evenity, a novel bone-builder that reduces bone loss, is seeking for healthcare reimbursement in Korea. According to pharmaceutical industry sources, Amgen Korea has recently submitted an application for healthcare reimbursement on Evenity (romososumab) with a dual effect of increasing bone formation and to a lesser extent reducing bone
- Company
- Boryung, acquires domestic sales rights for Lilly's GemZar
- by Kim, Jin-Gu May 13, 2020 05:53am
- Boryung acquired the domestic right for the anticancer drug 'GemZar (Gemcitabine HCl)' held by Eli Lilly. Boryung announced on the 8th that it had signed a contract to transfer assets to Eli Lilly and Gemzar. Through this agreement, Boryung has all rights, including domestic rights and licenses of Gemzar. Boryung and Eli Lilly have been co
- Company
- Itaewon club-linked COVID-19 threatens the industry
- by An, Kyung-Jin May 12, 2020 06:28am
- The pharmaceutical industry is straining as the number of confirmed COVID-19 from Seoul Itaewon Club increases. Pharmaceutical companies in the Seoul Square building where COVID-19 confirmed patients visited Itaewon went into emergency telecommuting, and nearby pharmaceutical companies are also watching closely. According to the industry
- Company
- Delay in choline alfoscerate reimbursement reevaluation
- by Kim, Jin-Gu May 12, 2020 06:28am
- The sources speculate the Korean pharmaceutical industry’s hot potato, the reimbursement feasibility reevaluation on choline Alfoscerate would be postponed to the latter half of the year. On May 11, pharmaceutical industry sources reported the reimbursement reevaluation on choline alfoscerate has been pressed on since the last year’s N
- Company
- Teva gave Celltrion ₩200 billion in copyright deposit
- by An, Kyung-Jin May 12, 2020 06:27am
- Celltrion group surpassed the exclusive rights of the two biosimilars in North America, and it was found that it generated a technology fee of nearly &8361;200 billion. In a report submitted to the Securities and Exchange Commission (SEC) on the 7th (local time), multinational pharmaceutical company Teva revealed the history of a biosi
- Company
- Samsung Biologics, ranked No.1 in the market cap
- by An, Kyung-Jin May 11, 2020 06:19am
- Samsung Biologics is taking third place in the market capitalization of KOSPI with the reflex profit of COVID-19. Difference in market capitalization with Celltrion is about &8361;10 trillion, and it has been holding a position as a bio leading stock for 7 months. According to the Korea Exchange on the 8th, Samsung Biologics closed th
- Company
- COVID-19 affected off-patent drug market share plunge?
- by Chon, Seung-Hyun May 11, 2020 06:18am
- Although off-patent originals have been consistently expanded their market shares in recent years unaffected by the army of generics entering the market, the original’s market share shrunk in last first quarter. The Korean pharmaceutical industry experts analyze the originals struggled to grow in the market against intense marketing of generics
